Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF REVENUE RECOGNITION (Details) (Parenthetical)

v3.24.2.u1
SCHEDULE OF REVENUE RECOGNITION (Details) (Parenthetical) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Product Information [Line Items]        
Revenue $ 2,397,652 $ 19,738 $ 4,804,043 $ 20,659
Health Care, Patient Service [Member]        
Product Information [Line Items]        
Revenue [1]     4,209,955
Health Care, Patient Service [Member] | CyPath® Lung [Member]        
Product Information [Line Items]        
Revenue     $ 199,000  
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $199,000.